NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Gastroesophageal Junction (Siewert I-III) Adenocarcinoma;
Intravenous Chemotherapy;
Progression Free Survival;
Peritoneal Metastasis;
Intraperitoneal Chemotherapy

Recruitment Keyword(s)



Gastric Adenocarcinoma;
Gastric Cancer;
Esophagogastric Junction;
Peritoneal Carcinomatosis

Investigational Drug(s)


Investigational Device(s)



Drug: Paclitaxel
Drug: Capecitabine
Device: BardPort Titanium Implanted Port with Peritoneal Catheter

Supporting Site

National Cancer Institute


Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live longer and delay the time it takes for the cancer to grow.


To find a better way to treat advanced stomach cancer.


People ages 18 and older with stomach cancer that has spread throughout their belly.


Participants will be screened with:

Medical history

Physical exam

Blood, urine, and heart tests


Cancer sample: If they do not have one, they will have a biopsy.

Tests of performance of normal activities

Dietary assessment

Participants will have a laparoscopy. Small cuts are made into their abdomen. A thin camera with a light is inserted. Small instruments are used to take biopsies. This will be repeated during the study to monitor the cancer. During the first laparoscopy, a port with a catheter attached will be put into the abdomen.

Participants may also have an endoscopy: A thin tube with a camera is inserted through the mouth and into the stomach. The tube collects samples to monitor the cancer.

Participants will get paclitaxel every 3 weeks through the abdominal port and through a small plastic tube in an arm vein. They will also take capecitabine by mouth twice daily for the first 15 days of a 21-day cycle.

After participants finish 3 cycles, they will have scans to see how they are doing. They may get another course of therapy.

Participants will have visits every 3 weeks during treatment. Then they will have follow-up visits for 5 years. Then they will keep in touch with researchers for the rest of their life.

--Back to Top--



1. Patients must have histologically or cytologically confirmed gastric adenocarcinoma, including Siewert III gastroesophageal junction adenocarcinoma, confirmed by the NCI Laboratory of Pathology, and have provided a block or unstained slides of primary or

metastatic tumor tissue or newly obtained fresh biopsy of a tumor lesion in case archival tissue sample is not available.

2. Patients may be treatment na(SqrRoot) ve or have received systemic chemotherapy prior to enrollment:

-Trastuzumab allowed as prior treatment for HER2/neu over-expressing cancers as clinically indicated.

-Last dose of chemotherapy at least 2 weeks prior to enrollment with recovery to Grade 1 from chemotherapy-related toxicities.

3. Radiographic evidence of peritoneal carcinomatosis and/or sub-radiographic evidence of peritoneal carcinomatosis found at staging laparoscopy.

4. Age >=18 years. Children under the age of 18 will not participate in this study as gastric cancer is rare in this population.

5. ECOG performance status <=1

6. Patients must have normal organ and marrow function as defined below:

hemoglobin >=8.0 g/dL

absolute neutrophil count >=1,000/mcL

platelets >=100,000/mcL

total bilirubin <=1.5 X institutional upper limit of normal

AST(SGOT)/ALT(SGPT) <=2.5 X institutional upper limit of normal

creatinine <1.5 mg/dl


creatinine clearance >=60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.

7. Physiologically able to undergo laparoscopy and systemic chemotherapy.

8. Ability of subject to understand and the willingness to sign a written informed consent document.

9. Previous exploratory laparotomy or laparoscopy with tissue biopsy or peritoneal lavage is permitted.

10. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

11. Patients must be co-enrolled in protocol 13C0176 (NCT01915225) and 17C0044 (NCT03027427) for sample collection.

12. HIV-positive patients may be considered for this study only after consultation with a NIAID physician.


1. Patients who are receiving any other investigational agents.

2. Previous cytoreductive surgery or intraperitoneal chemotherapy.

3. Disseminated extra-peritoneal or solid organ metastases:

-Excludes greater omentum and ovarian metastases.

-Radiographic signs or clinical symptoms consistent with malignant bowel obstruction.

4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Paclitaxel or Capecitabine or other agents used in study.

5. Previous treatment with paclitaxel or nab-paclitaxel resulting in progression of disease.

6. Existing peripheral neuropathy, Grade 3 or greater.

7. Past medical history of dihydropyrimidine dehydrogenase deficiency.

8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

9. Pregnant women are excluded because paclitaxel and capecitabine can cause fetal harm when administered to pregnant women. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel and capecitabine, breastfeeding should be discontinued if the mother is treated with paclitaxel and capecitabine.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Jeremy L. Davis, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 4-3742
(240) 858-3731

Cathleen E. Hannah
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 4-5740
10 Center Drive
Bethesda, Maryland 20892
(240) 409-8860

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--